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ABSTRACT 27 
Alveolar macrophages (AM) play pivotal roles in modulating host defense, pulmonary inflammation and 28 
tissue injury following respiratory viral infections. However, the transcriptional regulation of AM 29 
function during respiratory viral infections is still largely undefined. Here we have screened the 30 
expression of 84 transcription factors in AM in response to influenza A virus (IAV) infection. We found 31 
that the transcription factor PPAR-γ was downregulated following IAV infection in AM through type I 32 
interferon (IFN)-dependent signaling. PPAR-γ expression in AM was critical for the suppression of 33 
exaggerated antiviral and inflammatory responses of AM following IAV and respiratory syncytial virus 34 
(RSV) infection. Myeloid PPAR-γ deficiency resulted in enhanced host morbidity and increased 35 
pulmonary inflammation following both IAV and RSV infections, suggesting that macrophage PPAR-γ is 36 
vital for restricting severe host disease development. Using approaches to selectively deplete recruiting 37 
monocytes, we demonstrated that PPAR-γ expression in resident AM was likely important in regulating 38 
host disease development. Furthermore, we showed that PPAR-γ was critical for the expression of wound 39 
healing genes in AM. As such, myeloid PPAR-γ deficiency resulted in impaired inflammation resolution 40 
and defective tissue repair following IAV infection. Our data have suggested a critical role of PPAR-γ 41 
expression in lung macrophages in modulating pulmonary inflammation, the development of acute host 42 
diseases and the proper restoration of tissue homeostasis following respiratory viral infections. 43 
 44 
IMPORTANCE: Respiratory viral infections, like IAV and respiratory syncytial virus (RSV) infections, 45 
impose great challenges to the public health. Alveolar macrophages (AM) are lung resident immune cells 46 
that play important roles in protecting the host against IAV and RSV infections. However, the underlying 47 
molecular mechanisms by which AM modulating host inflammation, disease development and tissue 48 
recovery are not very well understood. Here we identify that PPAR-γ expression in AM is crucial to 49 
suppress pulmonary inflammation and diseases, and to promote fast host recovery from IAV and RSV 50 
infections.  Our data suggest that targeting macrophage PPAR-γ may be a promising therapeutic option in 51 
the future to suppress acute inflammation and simultaneously promote recovery from severe diseases 52 
associated with respiratory viral infections.  53 
  54 
 55 
 56 
 57 
 58 
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INTRODUCTION 60 
Acute respiratory viral infections, such as influenza A virus (IAV) and respiratory syncytial virus (RSV) 61 
infections, cause severe morbidity and mortality, and are among leading causes of death in children and 62 
the elderly (1, 2). Particularly, IAV virus infection kills ~500,000 people globally and up to 50,000 people 63 
in the United States each year (3). In addition to seasonal outbreaks, pandemic IAV viruses occasionally 64 
emerge and can cause catastrophic illness and widespread death. Current strategies for IAV prevention 65 
and treatment include yearly vaccination and anti-viral drugs. However, frequent changes in the surface 66 
antigens of IAV virus due to antigenic shift and drift can allow IAV to escape antibody-mediated 67 
immunity following vaccination (4, 5). Anti-viral treatment is generally only effective during a very short 68 
time period early after IAV infection. Furthermore, many circulating IAV strains have developed 69 
resistance to the current antiviral drugs (6). Thus, there is urgent need to better understand the 70 
pathophysiology and the protective immune responses to IAV infection for the development of future 71 
preventive and therapeutic means.  72 
 73 
The disease pathogenesis associated with IAV infection results from a combination of the deleterious 74 
effects of virus replication and the host innate and adaptive immune response associated with control and 75 
ultimately clearance of virus (7, 8). The major contribution of the host response to lung injury during IAV 76 
infection is exemplified by the immune-mediated lung inflammation and injury associated with infections 77 
with the 1918 pandemic IAV or the highly pathogenic H5N1 avian IAV. The inability to control the host 78 
responses in these infections results in excessive inflammatory cell infiltration into the lungs and 79 
overproduction of pro-inflammatory mediators ((9, 10).  80 
 81 
As important components of innate immunity, tissue macrophages and monocyte populations are 82 
heterogeneous multifunctional immune sentinel cells important in modulating tissue homeostasis, 83 
inflammation, injury and repair (11-15). The main macrophage population in the respiratory tract is 84 
alveolar macrophages (AM) that play important roles in lung homeostasis and pulmonary anti-microbial 85 
defense (16, 17). Compared to other tissue macrophages, monocytes and monocyte-derived cells, AM 86 
have distinct functions and phenotypes that include high autofluorescence, low CD11b expression, and 87 
high expression of CD11c and Siglec-F (16, 18). AM precursors develop mainly from fetal monocytes, 88 
which seed the lung prior to birth, and massively expand and develop into mature macrophages in 89 
response to GM-CSF and TGF-β after birth (18-20). A number of factors including PPAR-γ, mTORC1, 90 
phosphoinositide kinase PIKfyve and L-plastin were also recently shown to be important in AM 91 
development and function (19, 21-24). Interestingly, AM appear to be essential for the protection against 92 
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IAV and other respiratory viral infections (25-31) . To this end, AM were identified as a major cellular 93 
source of the antiviral cytokines, type I interferons (IFNs) (29). Furthermore, AM can phagocytize virus 94 
and virus infected cells, clear cellular debris and exudates, and protect alveolar type I cells (ATI) from 95 
infection, thereby suppressing the development of lethal inflammation and injury during IAV infection 96 
(25-31). AM, particularly AM undergoing alternative polarization (M2), have also been implicated in the 97 
repair of damaged tissues following IAV infection (32). However, the underlying molecular mechanisms 98 
regulating the protective function of AM against respiratory viral infections remain to be fully elucidated.  99 
 100 
PPAR-γ is a nuclear transcription factor, usually forming heterodimer with RXR (retinoid X receptor) 101 
which recruit different co-activators or co-repressors to form a complex binding to PPAR-responsive 102 
regulatory elements in the genome to modulate the expression of genes involved in adipogenesis, lipid 103 
metabolism and inflammation (33). PPAR-γ has been shown to be vital for M2 polarization and the 104 
restriction of excessive production of inflammatory factors (34, 35), although the roles of PPAR-γ in 105 
regulating macrophage inflammatory responses against viral infections have not been explored.  AM 106 
constitutively express high levels of PPAR-γ (19). Mice with loxP-flanked alleles encoding PPAR-γ 107 
(Pparg
fl/fl
) and with CD11c-driven expression of Cre recombinase (Cd11c–cre) that is efficiently 108 
expressed in fetal monocytes, exhibit severe defects in the AM compartment, suggesting that PPAR-γ is 109 
essential for AM development from fetal monocytes (19).  Interestingly, prophylactic or therapeutic 110 
treatment of mice with natural or synthetic ligands which activate PPAR-γ resulted in diminished host 111 
morbidity and mortality during IAV infection (36-40) . However, the cellular and molecular mechanisms 112 
by which PPAR-γ agonists promote host protection against IAV infection have not been defined. In 113 
addition, the physiological and cell type-specific function of PPAR-γ in response to endogenous ligands 114 
during IAV infection are currently unknown. 115 
 116 
In this report, we demonstrated that PPAR-γ was down-regulated in AM via IFNs following IAV 117 
infection. PPAR-γ repressed macrophage pro-inflammatory responses and promoted the expression of 118 
wound healing gene programs independent of M2 polarization, thereby modulating lung inflammation, 119 
host morbidity and tissue repair. We further showed that PPAR-γ expression and function in AM were 120 
likely important in dictating host diseases and recovery from respiratory viral infection. 121 
 122 
 123 
 124 
RESULTS 125 
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IAV infection downregulates PPAR-γ expression in macrophages through IFNs 126 
AM are important in regulating antiviral immunity and injury. However, the molecular mechanisms 127 
regulating AM responses to viral infection are still not well understood. To explore the transcriptional 128 
regulation of AM responding to viral infection, we infected WT AM with IAV PR8 (IAV, 10 MOI) in 129 
vitro and then determined the expression of 84 transcription factors (TFs) following overnight culture 130 
using Qiagen RT
2
-PCR array. We found that a numbers of TFs involved in antiviral innate immunity were 131 
upregulated, while several TFs including Pparg were downregulated in AM following IAV infection 132 
(Figure 1 A and B). Quantitative PCR results also showed that Pparg was downregulated in AM 133 
following IAV infection (Figure 1 C). Western blot analysis confirmed decreased PPAR-γ at the protein 134 
level in IAV infected AM (Figure 1 D). To determine whether IAV infection downregulates Pparg in AM 135 
in vivo, we sorted AM (CD11c
+
/Siglec F
+
) from the lungs of uninfected (day 0) or IAV-infected mice (4, 136 
6, 10 or 15 days post infection (d.p.i.)) and examined Pparg expression by realtime RT-PCR (Figure 1 E). 137 
We found that IAV infection diminished Pparg expression in AM, particularly at 6 d.p.i. (Figure 1 E). 138 
Western blot analysis confirmed that AM isolated from IAV-infected mice (6 d.p.i.) exhibited decreased 139 
PPAR-γ protein levels compared to AM isolated from uninfected mice (Figure 1 F). IAV infection 140 
triggers the production of anti-viral cytokines type I IFNs by AM (6). We next examined whether type I 141 
IFNs were involved in the regulation of PPAR-γ expression in AM. We found that IFN-α treatment 142 
suppressed PPAR-γ expression in AM (Figure 1 G). Next, we infected AM with IAV and then blocked 143 
type I IFN signaling with the inclusion of IFNAR1 blocking antibody (α-IFNAR1) in culture. We found 144 
that α-IFNAR1 treatment abolished IAV-induced suppression of Pparg expression in AM (Figure 1H). 145 
Similarly, α-IFNAR1 treatment abolished Poly IC induced suppression of Pparg expression in AM 146 
(Figure 1H).   Together, these data suggest that IAV infection inhibited PPAR-γ expression in AM 147 
through IFN signaling.  Consistent with the notion, we found that STAT1 could bind to Pparg locus 148 
following IFN-α treatment, suggesting that STAT1 activation following IFN signaling may directly 149 
modulate Pparg transcription in AM (Figure 1I).  150 
 151 
PPAR-γ suppresses antiviral inflammation, but does not regulate M2 genes following infection 152 
PPAR-γ is required for AM development because the deletion of PPAR-γ in CD11c+ cells (PpargΔCD11c) 153 
resulted in impaired AM generation (Figure 2A and (19)). However, compared to CD11c-cre, Lyz2-cre 154 
expression in fetal monocytes is incomplete (19). As the result, Lyz2-cre driven PPAR-γ deficiency 155 
(Pparg
ΔLyz2
) in AM resulted in relatively normal AM development (Figure 2A and (19). In comparison to 156 
the severe defects of AM development and maturation (evidenced by dramatic increase of CD11b (19)) 157 
observed in Pparg
ΔCD11c
 mice, Pparg
ΔLyz2
 mice had comparable percentages of AM and only slightly 158 
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increased CD11b expression compared to those of control mice, suggesting that AM development and 159 
maturation were relatively normal in Pparg
ΔLyz2
 mice (Figure 2A). Nevertheless, Lyz2-cre is able to 160 
mediate gene recombination in adult AM compartments and AM from adult Pparg
ΔLyz2 
mice exhibited 161 
impaired PPAR-γ expression (Figure 2 B and (30)). We therefore used AM from littermate control 162 
(Pparg
fl/fl
, WT) or Pparg
ΔLyz2
 mice for our further analysis on the roles of PPAR-γ in regulating AM 163 
function during respiratory viral infections. We first isolated AM from uninfected control or Pparg
ΔLyz2
 164 
mice, and infected the AM with IAV in vitro as in Figure 1. Following infection, WT and Pparg
ΔLyz2 
AM 165 
showed relatively comparable levels of viability (data not shown). We then examined the expression of 166 
type I IFNs, inflammatory cytokines and M2 genes in control or PPAR-γ-deficient AM following IAV 167 
infection. We found that PPAR-γ deficiency enhanced the expression of Ifna4, Ifnb1, Tnf, Il1b and Ccl2 168 
expression, but did not affect the expression of Retnla (encoding RELM-α protein) and Arg1 (encoding 169 
Arginase 1 protein) (Figure 2C).  These data suggest that PPAR-γ suppressed AM antiviral and 170 
inflammatory responses, but did not change macrophage polarization following IAV infection. We next 171 
infected control or Pparg
ΔLyz2
 mice with IAV and then sorted AM from the lungs of infected mice at 1 or 172 
3 d.p.i. We found that PPAR-γ deficient AM exhibited enhanced type I IFN and inflammatory gene 173 
expression, but showed similar levels of Retnla and Arg1 expression compared to those of control AM at 174 
3 d.p.i. (Figure 2D). These data suggest PPAR-γ functioned to inhibit antiviral and inflammatory 175 
responses, but did not regulate M2 polarization following IAV infection. 176 
 177 
Myeloid PPAR-γ suppresses lung inflammation, host morbidity and mortality  178 
To explore PPAR-γ expression in macrophages in regulating host antiviral responses and disease 179 
development following IAV infection, we infected control or Pparg
ΔLyz2
 mice with IAV and examined 180 
host mortality, morbidity, viral replication and inflammatory responses at different days post infection. 181 
Compared to control mice, Pparg
ΔLyz2 
mice had enhanced host mortality and morbidity, and delayed 182 
weight recovery following IAV infection (Figure 3 A, B). We examined the kinetics of IAV replication in 183 
the respiratory tract using plaque forming unit (pfu) assay and found that Pparg
ΔLyz2
 mice exhibited 184 
significant increased virus titers early days following IAV infection (4 d.p.i.) compared to control mice 185 
(Figure 3C). However, Pparg
ΔLyz2
 mice had comparable viral titers at 7 d.p.i. and most of the mice cleared 186 
their infectious virus around 10 d.p.i. (3 out of 11 mice exhibited detectable viruses in control or 187 
Pparg
ΔLyz2
 bronchoalveolar lavage fluid (BAL)) (Figure 3 C). Thus, Pparg
ΔLyz2
 mice showed similar viral 188 
clearance kinetics as control mice and suggest that the enhanced morbidity and mortality observed in 189 
Pparg
ΔLyz2 
mice was not merely due to the failure of viral clearance. Consistent with the viral clearance 190 
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data, we found that Pparg
ΔLyz2
 mice exhibited comparable levels of IAV-specific CD8
+
 T cell responses 191 
(both H2d
b
 NP366-374 tetramer
+
 and H2d
b
 PA224-233 tetramer
+
) at 7, 10 and 15 d.p.i. (Figure 3D).  192 
 193 
Next, we measured lung inflammatory cytokine (CCL2 and TNF-α) levels in the BAL at different days 194 
following IAV infection to determine whether Pparg expression in myeloid cells regulates pulmonary 195 
inflammation. We found that Pparg
ΔLyz2
 mice had significant higher CCL2 and TNF-α levels at early days 196 
post IAV infection (i.e. 1 or 3 d.p.i.) (Figure 3E). Notably, although the differences did not reach 197 
statistical significance, Pparg
ΔLyz2
 mice showed trend of increased CCL2 protein levels in the BAL at 7, 198 
10 or 15 d.p.i., indicating that Pparg
ΔLyz2
 mice may have modest increased pulmonary inflammation at 199 
later days post infection. To this end, we used a more sensitive approach to examine inflammatory gene 200 
expression in the lungs of control or Pparg
ΔLyz2 
mice by Qiagen RT
2
-PCR array. We found that lungs of 201 
Pparg
ΔLyz2
 mice exhibited altered expression of inflammation-related genes including higher expression of 202 
a number of pro-inflammatory genes (such as Il6, Cxcl1 and Fos) at day 10 d.p.i. (Figure 3 F).  Taken 203 
together, these data suggest that myeloid PPAR-γ deficiency leaded to enhanced early viral replication, 204 
exuberant inflammatory reaction and increased severity of host sickness. 205 
 206 
Myeloid PPAR-γ inhibits inflammation and morbidity during RSV infection 207 
To examine whether PPAR-γ controls AM inflammatory responses to other virus infection, we infected 208 
isolated AM from control or Pparg
ΔLyz2
 mice with RSV, a virus that affects millions of children. Similar 209 
to what we have observed following IAV infection (Figure 2C), we found that PPAR-γ deficiency 210 
enhanced Ifna4, Ifnb1, Tnf, Il1b and Ccl2 expression following RSV (line 19, 10 MOI) infection in vitro, 211 
suggesting that PPAR-γ also controls antiviral and inflammatory responses against RSV infection (Figure 212 
4A). We then infected control or Pparg
ΔLyz2
 mice with RSV (line 19) and examined host morbidity and 213 
lung inflammatory responses. We found that myeloid PPAR-γ deficiency increased weight loss following 214 
RSV infection (Figure 4 B). We also found that Pparg
ΔLyz2
 mice had enhanced inflammatory innate 215 
immune cells (neutrophils and monocytes) present in the lungs at 4 d.p.i. (Figure 4C), suggesting that 216 
Pparg
ΔLyz2
 mice had higher pulmonary inflammation compared to control mice. Consistently, BAL of 217 
Pparg
ΔLyz2
 mice had higher TNF-α and IL-1β levels compared to those of control mice at 4 d.p.i. (Figure 218 
4D). Thus, myeloid PPAR-γ was required for the suppression of exuberant host inflammation and 219 
exaggerated morbidity following RSV infection. These data suggest that macrophage PPAR-γ may 220 
restrict host disease development in a broad spectrum of respiratory viral infections.  221 
PPAR-γ expression in resident AM is likely required for controlling host disease development 222 
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Lysozymes are widely expressed in myeloid cells including neutrophils, monocytes and macrophages. We 223 
crossed Lyz2-cre mouse with a cre reporter strain R26R-eYFP mouse to examine Cre deletion in the 224 
myeloid compartment. In agreement with previous report (35), we observed Lyz2-cre activity in majority 225 
of alveolar macrophages and neutrophils, partially in CD11b
+
 monocytes/macrophages (Figure 5A). 226 
Western-blot analysis on sorted myeloid cell populations isolated from the lungs revealed that AM 227 
expressed high levels of PPAR-γ and lung CD11b+ monocyte/macrophage population expressed 228 
comparatively lower levels of PPAR-γ (Figure 5B), while neutrophils did not express detectable PPAR-γ, 229 
which is consistent with previous reports (35) (Figure 5B). To explore the potential roles of PPAR-γ in 230 
regulating inflammation of AM, monocytes/monocyte-derived macrophages and/or epithelial cells, we 231 
sorted AM, CD11b
+
 monocytes/macrophages and CD45
- 
(mainly epithelial cells) from IAV-infected 232 
lungs of control or Pparg
ΔLyz2
 mice at 1 and 3 d.p.i. and examined inflammatory cytokine expression. We 233 
found that elevated Tnf and Ccl2 expression was mainly observed in AM, but not in CD11b
+
 234 
monocytes/macrophages nor in CD45
-
 cells (Figure 5C). We next explored the relative contributions of 235 
PPAR-γ in AM and monocytes/monocyte-derived macrophages in controlling host disease development 236 
during IAV infection. To this end, we crossed Pparg
ΔLyz2
 mice to Ccr2
-/-
 mice to block monocyte traffic to 237 
the infected lungs (40-43). We found that, compared to Ccr2
-/-
/Pparg
fl/fl
 mice, Ccr2
-/-
/Pparg
ΔLyz2
 mice lost 238 
more weight and exhibited delayed recovery (Figure 5D), suggesting that enhanced disease development 239 
in Pparg
ΔLyz2
 mice is independent of monocytes or monocyte-derived cells. We next assessed whether 240 
treatment of anti-CCR2 (MC21 mAb), which selectively depletes recruiting monocytes (44) could affect 241 
host morbidity in Pparg
ΔLyz2
 mice. As reported (43), MC21 treatment greatly decreased monocyte 242 
infiltration to the lung (Figure 5E). However, MC21 treatment did not significantly alter host weight loss 243 
in neither control nor Pparg
ΔLyz2
 mice (Figure 5F), again suggesting that monocytes are dispensable for 244 
phenotypes observed in Pparg
ΔLyz2
 mice following IAV infection. Taken together, these data suggest that 245 
PPAR-γ expression in AM, rather than in monocytes or monocyte-derived cells, is probably responsible 246 
for the restriction of exaggerated pulmonary inflammation and the suppression of the development of 247 
severe diseases following respiratory viral infection. 248 
 249 
Macrophage PPAR-γ promotes tissue repair 250 
Following the clearance of IAV, the inflammatory responses in the lung resolve and the damaged tissue 251 
undergoing repair process to restore normal tissue homeostasis. AM are thought to be involved in the 252 
tissue repair process following lung injury (32). We therefore examined whether PPAR-γ affects AM 253 
tissue repair function. To this end, we isolated control or PPAR-γ-deficient AM from WT or PpargΔLyz2 254 
mice and performed Qiagen RT
2
-PCR array to determine wound healing gene expression. We found that 255 
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PPAR-γ deficiency resulted in impaired expression of a large numbers of wound healing-related genes 256 
including epithelial and endothelial growth factors such as Vegf, Egf and Fgf7 (Figure 6 A, B). A numbers 257 
of factors involved in tissue remodeling including Mmp7, Mmp9 and Timp1 were also decreased in 258 
PPAR-γ-deficient AM (Figure 6 A, B). These data suggested that PPAR-γ expression is important in 259 
regulating wound healing and tissue repair function of AM.  260 
 261 
Therefore, we examined whether Pparg
ΔLyz2
 mice had impaired tissue recovery in vivo following viral 262 
clearance. To this end, we examined lung histopathology with Hematoxylin and Eosin (H&E) staining of 263 
lung sections at 15 d.p.i., when infectious virus has been cleared from IAV infection (Figure 3C). We 264 
found that Pparg
ΔLyz2 
mice still had significant higher proportions of the inflamed and/or damaged areas 265 
that were not properly repaired at day 15 p.i., when mice already recovered most of their lost weight 266 
(Figure 3B and 6 C). To further explore the roles of myeloid PPAR-γ in regulating lung inflammation 267 
resolution and tissue repair, we first examined airway inflammatory cell content (monocytes and 268 
neutrophils, reflection of lung inflammatory resolution). We found that Pparg
ΔLyz2
 mice exhibited higher 269 
neutrophil numbers at 15 d.p.i., suggesting that Pparg
ΔLyz2
 mice had impaired pulmonary inflammation 270 
resolution (Figure 6 D). We also measured total protein concentrations in the BAL (reflection of 271 
endothelial/epithelial leakage) at different days following IAV infection and observed that Pparg
ΔLyz2
 272 
mice had drastically higher protein levels in the BAL compared to those of control mice at 15 d.p.i 273 
(Figure 6 E). These data indicate that Pparg
ΔLyz2
 mice had impaired inflammation resolution and 274 
decreased damage repair. In further support of this view, we examined alveolar type II (AT II) epithelial 275 
gene expression in the lungs of control and Pparg
ΔLyz2
 mice as a surrogate of tissue recovery at 8, 10 or 15 276 
d.p.i. We found that ATII specific genes, Sftpb and Abca3, were comparable between control and 277 
Pparg
ΔLyz2
 lungs at 8 d.p.i. However, lungs of Pparg
ΔLyz2
 mice exhibited lower Sftpb and Abca3 278 
expression compared to those of control mice at 10 or 15 d.p.i. (Figure 6 F), indicating that lungs of 279 
infected Pparg
ΔLyz2
 mice had diminished ATII cell regeneration and lung recovery during viral clearance. 280 
Taken together, these data suggest that PPAR-γ promoted AM tissue repair function and myeloid-281 
deficiency of PPAR-γ resulted in diminished inflammation resolution and impaired tissue recovery 282 
following IAV infection. 283 
 284 
 285 
 286 
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DISCUSSION 287 
The transcriptional regulation of lung macrophage responses against respiratory viral infections is largely 288 
undefined. Here we identify that PPAR-γ expression in AM is vital for their proper responses during both 289 
IAV and RSV infection. PPAR-γ is an anti-inflammatory transcription factor able to antagonize NF-b-290 
mediated cytokine production constitutively and in response to TLR ligand stimulation (45). Consistent 291 
with the notion, we showed that PPAR-γ-deficient AM produced increased levels of both antiviral and 292 
pro-inflammatory cytokines in response to IAV and RSV infection. Notably, AM constitutively express 293 
high levels of PPAR-γ, which may help to maintain a tolerogenic environment in the lung during 294 
homeostasis. However, AM can also rapidly produce inflammatory cytokines following microbial 295 
challenge (17, 46). The down-regulation of PPAR-γ in AM may help the AM to rapidly respond to certain 296 
microbial challenges and provide beneficial functions under certain conditions. Nevertheless, the 297 
complete loss of PPAR-γ in macrophages caused exaggerated release of inflammatory mediators and 298 
enhanced disease development in vivo following IAV and RSV infections. These data suggest that PPAR-299 
γ counter-regulates the pathogenic inflammatory responses in vivo, and acts to ensure the proper function 300 
of lung macrophages during respiratory viral infections.  301 
 302 
The differential functions of AM and recruited monocyte/macrophage populations during homeostasis 303 
and disease conditions have only begun to be appreciated. During respiratory viral infections, circulating 304 
monocytes infiltrate the lungs in a CCR2-dependent manner and can give rise to exudate or inflammatory 305 
macrophages at the site of infection (42). These CCR2-dependent inflammatory monocytes and 306 
monocyte-derived cells have been associated with the development of immunopathology, although these 307 
cells also contribute to the normal antiviral responses as the blockage of their migration to the lung due to 308 
CCR2 inhibition or deficiency impaired and/or delayed host viral clearance during RSV and IAV 309 
infections (31, 40-42, 44). Notably, CCR2 deficiency or CCR2 blockade did not significantly change 310 
overall host morbidity in PPAR-γ sufficient or deficient background in our experimental system than what 311 
was reported before(31, 41), in which CCR2 deficiency significantly diminished host morbidity and 312 
mortality.  Variations in infection schemes, virus stocks and/or microbiota (46) may contribute to the 313 
different results observed. However, our results are supported by the findings of Aldridge et al (40), in 314 
which Ccr2
-/-
 deficient mice exhibited similar morbidity and mortality as WT mice following IAV 315 
infection.  316 
 317 
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In contrast, lung resident AM are often beneficial to the host during respiratory viral infections as AM 318 
depletion impairs host antiviral responses with concomitant development of severe lung injury during 319 
respiratory viral infections (25-31). However, AM do release inflammatory mediators following viral 320 
infections and thus may contribute to the development respiratory inflammation and/or injury if their 321 
responses are not tightly regulated. Multiple lines of evidence present in this study suggest that PPAR-γ 322 
expression in AM rather than in monocytes and/or monocyte-derived cells is important in controlling host 323 
inflammation and subsequent disease development. First, AM expressed high levels of PPAR-γ compared 324 
to monocytes and monocyte-derived cells. Furthermore, sorted AM rather than monocytes or monocyte-325 
derived cells exhibited increased inflammatory responses. Finally, disruption of monocyte recruitment 326 
into the lungs by using anti-CCR2 or genetic CCR2 deletion did not majorly impact the outcome of IAV 327 
infection in WT and myeloid PPAR-γ deficient mice, suggesting that PPAR-γ expression in monocytes 328 
may be dispensable for the regulation of the development of severe diseases following respiratory viral 329 
infection. Interestingly, PPAR-γ expression also regulated the wound healing function of AM and tissue 330 
recovery through the promotion of various growth factors and tissue remodeling factors. Notably, PPAR-γ 331 
deficiency did not result in decreased M2 gene expression in AM with or without IAV or RSV infection, 332 
suggesting that PPAR-γ may regulate AM repair function independent of M2 polarization. Thus, PPAR-γ 333 
is vital for the proper function of AM during respiratory viral infection by restricting their inflammatory 334 
features and simultaneously promoting their repair roles. 335 
 336 
Type I IFNs are widely recognized as host-beneficial, anti-viral cytokines. They lead to the transcription 337 
of IFN-stimulated genes that aim to eliminate the virus and prevent its spread by promoting anti-viral 338 
state in nearby cells (47). However, type I IFNs are also the key initiators of pulmonary inflammatory 339 
responses during respiratory viral infections and thus their actions must also be finely balanced to 340 
maximize viral clearance while inflicting minimal damage to the tissue (48). Indeed, the exaggerated 341 
production of type I IFNs have been implicated in the development of exuberant pulmonary inflammation, 342 
severe host morbidity and mortality following respiratory viral infections (44, 49, 50). In this report, the 343 
enhanced type I IFN production was observed in PPAR-γ deficient AM, but the absence of PPAR-γ in 344 
AM resulted in significantly increased viral titers at four days following IAV infection, suggesting that 345 
the enhanced production of type I IFNs by PPAR-γ-deficient AM was not sufficient to diminish viral 346 
replication in the lungs. The exact reasons underlying the phenomenon warrant further investigation.   347 
Nevertheless, given the potential inflammatory function of type I IFNs, it is possible that the altered 348 
production of type I IFNs along with the dysregulated inflammatory cytokine production in PPAR-γ 349 
deficient AM contribute to the severe outcome of IAV infection in the myeloid PPAR-γ deficient mice.  350 
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 351 
In summary, our findings have uncovered critical roles of PPAR-γ in regulating inflammatory responses 352 
of AM, the development of acute host disease and the proper restoration of tissue homeostasis following 353 
respiratory viral infections. Further studies are warranted to examine the therapeutic potential of 354 
modalities that can specifically modulate the expression of PPAR-γ in AM for the treatment of severe 355 
respiratory viral infections and their associated pathologies.  356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
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 368 
 369 
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Mouse and infection. WT C57/BL6 mice were purchased from the Jackson Laboratory. Lyz2-cre, 393 
CD11c-cre, Pparg
fl/fl
, R26R-eYFP, Ccr2
-/-
 were purchased from the Jackson Laboratory and bred in house. 394 
Pparg
ΔLyz2 
mice were generated by crossing Pparg
fl/fl 
mice with Lyz2-cre mice. Pparg
ΔCD11c
 were 395 
generated by crossing Pparg
fl/fl 
mice with CD11c-cre mice. Ccr2
-/-
 Pparg
fl/fl 
 and Ccr2
-/-
 Pparg
ΔLyz2
 mice 396 
were generated by crossing Pparg
fl/fl 
 or Pparg
ΔLyz2
 mice with Ccr2
-/-
 mice. Lyz2-cre R26R-eYFP reporter 397 
mice were generated by crossing R26R-eYFP mice with Lyz2-cre mice. All mice housed in a specific 398 
pathogen-free environment. For IAV infection, influenza A/PR8/34 strain (~200 pfu/mouse) was diluted 399 
in FBS-free DMEM media (Corning) on ice and inoculated in anesthetized mice through intranasal route 400 
as described before (51). Host mortality was determined based on humane endpoint (more than 30% 401 
weight loss or moribund) or deaths before humanely sacrifice.  For RSV infection, RSV (strain line 19, 402 
~5×10
6
 pfu/mouse) was diluted in FBS-free DMEM media (Corning) on ice and inoculated in 403 
anesthetized mice through intranasal route as described (52). 404 
 405 
AM culture and infection in vitro. AM were obtained from BAL. Briefly, alveolar lavages were pooled 406 
from BAL washes from 3-5 mice (PBS with 2 mM EDTA) and stored on ice. Red blood cell lysis was 407 
then performed in ACK lysis buffer (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA, pH 7.2) at room 408 
temperature for 2 min. Freshly isolated cells were rested in complete medium (RPMI-1640, 10% FBS, 1% 409 
Pen/Strep) for 4 h at 37 C̊ and 5% CO2. The non-adherent cells were discarded, and the plates were rinsed 410 
with warm PBS. For AM infection in vitro, seeded cells were infected with or without 10 MOI of IAV 411 
PR8 virus or RSV line 19 as indicated in the text for 1 hour and then cultured for overnight. For AM IFN 412 
treatment in vitro, 10
5
 AM were plated in 12-well plate and treated with 50 ng/ml IFN-α (BioLegend) or 413 
vehicle overnight in the presence of recombinant GM-CSF to keep AM alive (Biolegend, 10ng/ml). Cell 414 
lysates were analyzed by quantitative RT-PCR or western blot.  415 
 416 
Quantitative RT-PCR. mRNA from cultured AM (pooled from multiple mice), in vivo sorted AM 417 
(pooled from multiple mice) or homogenates from individual lungs as indicated in the text was isolated 418 
with Total RNA purification kit (Sigma) and treated with DNase I (Invitrogen). Random primers 419 
(Invitrogen) and MMLV reverse transcriptase (Invitrogen) were used to synthesize first-strand cDNAs 420 
from equivalent amounts of RNA from each sample. RT-PCR was performed with Fast SYBR Green 421 
PCR Master Mix (Applied Biosystems). qPCR was conducted in duplicates in QuantStudio3 (Applied 422 
Bioscience). Data were generated with the comparative threshold cycle (Delta CT) method by 423 
normalizing to hypoxanthine phosphoribosyltransferase (HPRT). Sequences of primers used in the studies 424 
are provided as follows. Abca3: TTCTGGTTCTCCGCTCTGTT, GTACATGAGGGGGATGATGG.  425 
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Arg1: CAATGAAGAGCTGGCTGGTG, TGAGCATCCACCCAAATGAC.  426 
Ccl2: GTCACCAAGCTCAAGAGAGAGGTC, CCTACAGAAGTGCTTGAGGTGGTT.  427 
Hprt: CTCCGCCGGCTTCCTCCTCA, ACCTGGTTCATCATCGCTAATC.  428 
Ifna4: TCCATCAGCAGCTCAATGAC, AGGAAGAGAGGGCTCTCCAG.  429 
Ifnb1: TCCACCAGCAGACAGTGTT, CTTTGCACCCTCCAGTAATAGC.  430 
Il1b: GGGCCTCAAAGGAAAGAATC, TACCAGTTGGGGAACTCTGC.   431 
Pparg: TGCCAGTTTCGATCCGTAGA, ATGAATCCTTGGCCCTCTGA.    432 
Retnla: TGCCCTGCTGGGATGACTGCT, GGACAGTTGGCAGCAGCGGG.  433 
Sftpb: CTGTGCCAAGAGTGTGAGGA, TTGGGGTTAATCTGGCTCTG.  434 
Tnf: CATGCGTCCAGCTGACTAAA, TCCCCTTCATCTTCCTCCTT. 435 
 436 
RT
2
 Profiler PCR Array. Total RNA from lung tissue or AM was extracted as described above. Equal 437 
amount of total RNA was used for the synthesis of first strand cDNA with kit from Qiagen. First strand 438 
cDNA was mixed with 2xFast SYBR Green Master Mix (Applied Bioscience) and water in a formula 439 
directed in the manual. 25 µl of the mixture was added into each well of the 96 well plate provided by 440 
manufacture. The wells in the plate include different primers in each well to detect 84 target genes, 441 
housekeeping genes, negative and positive control genes. qPCR was conducted in QuantStudio3 (Applied 442 
Bioscience). Obtained raw data was analyzed in software provided by Qiagen (accessible online on the 443 
website of Qiagen). Following the instruction step by step, upload Excel file, designating control group, 444 
select housekeeping gene to normalize result and calculate the relative expression quantity.  445 
 446 
Cell depletion. For monocyte depletion, mice were treated intraperitoneally (i.p.) with anti-CCR2 447 
antibody (clone: MC21, 25 μg/mouse in 200 μl of PBS)(53) or control IgG daily from day 0 to day 6.  448 
 449 
Lung histopathology. Following euthanasia, mice were perfused with PBS (10 mL) via the right 450 
ventricle. 10% paraformaldehyde (PF) was then gently instilled into the lung and left inflated for 1 minute 451 
before excising and moving lobe to 10% PF for 48 hours followed by transfer to ethanol (70%). Samples 452 
were shipped to Mayo Clinic Histology Core Lab (Scottsdale, AZ) where they were embedded in paraffin 453 
and 5 um sections were cut for Hematoxylin and eosin stain. To quantify percent of inflamed or disrupted 454 
alveolar area, H&E slides were scanned through the Aperio whole slide scanning system and exported to 455 
image files. Computer-based image analysis was performed using the Image J software (NIG, Bethesda, 456 
MD, USA). We first determined the total lung area by converting the image into gray scale followed with 457 
red highlighting through the adjustment of the Threshold. For determination of the inflamed and disrupted 458 
area, color images were split into single channels. We then used the green channel, highlighted the 459 
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inflamed areas in red by adjusting the Threshold and measured the areas based on pixel. The percentages 460 
of disrupted and inflamed lung areas were calculated based on the ratio of highlighted disrupted areas to 461 
the total lung area in each lung section. 462 
  463 
Western Blot analysis. Same numbers of cultured or FACS-sorted AM were lysed in lysis buffer 464 
(62.5mM Tris-HCL (pH 6.8), 2% SDS and 10% glycerol) with a protease inhibitor cocktail (Roche). The 465 
lysates were then separated by SDS-PAGE and transferred to Immuno-Blot Nitrocellulose Membrane 466 
(Bio-Rad,). The membranes were blocked with 5% non-fat milk in 20 mM Tris (pH 7.5), 0.5 M NaCl and 467 
0.05% Tween 20 (TBST) for 1h at room temperature (RT), followed by incubation with primary Ab 468 
against PPAR-γ (1:1000, Cell Signaling Technology) or β-actin (1:5000, Santa Cruz Biotechnology) 469 
overnight at 4°C. After washing with TBST buffer, membranes were incubated with goat anti-rabbit or 470 
anti-mouse secondary Ab (Promega). Peroxidase activity was detected with enhanced 471 
chemiluminesecence (ECL). 472 
 473 
Chromatin Immunoprecipitation (ChIP). AM were obtained from the lung of naïve WT C57BL6 mice, 474 
using anti-CD169 magnetic beads, as recommended by the manufacturer (Miltenyi Biotec). AM were 475 
cultured in complete medium supplemented with 10 ng/ml GM-CSF in the presence of 50 ng/ml IFN-α 476 
(BioLegend) or vehicle overnight. Then the cells were subjected to ChIP assay as previously described 477 
(54). In brief, 8x10
6
 AM were crosslinked for 10 min at 37 ̊C by the addition of 1% freshly made 478 
formaldehyde. Fixed cells were pelleted at 4 ̊C and washed with ice-cold PBS. The cells were lysed with 479 
SDS lysis buffer (1% SDS, 10mM EDTA, 50mM Tris, pH 8.1) containing protease inhibitors (Roche) on 480 
ice for 10 min and sonicated to an average size of 200-500bp. After sonication, samples were centrifuged 481 
at 13,000 rpm for 10 min at 4 ̊C and 5% of sonicated cell extracts were saved as input. The resulting 482 
whole-cell extract was incubated with Protein A/G Agarose (Santa Cruz) for 1h at 4 ̊C. Precleared extracts 483 
were then incubated with 60 ul of Protein A/G Agarose (Santa Cruz) for ChIP with 5μg of the appropriate 484 
antibody overnight at 4 ̊C. STAT1 ChIP antibody (clone D1K9Y) was from Cell Signaling.  After 485 
overnight incubation, beads were washed once with low salt immune complex wash buffer (0.1% SDS, 1% 486 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH 8.1, 150 mM NaCl), once with high salt immune 487 
complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH 8.1, 500 mM 488 
NaCl), once with LiCl wash buffer (10 mM Tris-HCl pH 8.1, 1 mM EDTA, 250 mM LiCl, 1% NP-40), 489 
and twice with TE wash buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA). DNA was eluted in freshly 490 
prepared elution buffer (1% SDS, 0.1M NaHCO3). Cross-links were reversed by overnight incubation 491 
with 5 M NaCl at 65 ̊C. RNA and protein were digested using RNase A and proteinase K (Roche), 492 
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respectively and DNA was purified by Qiagen MinElute PCR Purification kit according to the 493 
manufacturer’s instructions. The immunoprecipitated DNA was analyzed by quantitative real-time PCR 494 
and normalized relative to input DNA amount. Primers were designed to a segment that was centered on 495 
the PPAR-γ coverage regions. Primers used in this study are listed in as follows. Realtime PCR data is 496 
represented as fold levels over control. Primers sequence are as following.  Pparg -4.3k:  497 
TGGAATGAAAGAATCCTCCAA, GTTGGTGCCACATGGATTTT. Pparg -16.8k: 498 
GCAGATTTGTGCCAAGAACA, TGCAGCCGCTGAATAAATAC. 499 
 500 
ELISA analysis of BAL cytokines. 50 µl of each BAL sample was analyzed with the ELISA using 501 
commercially available kits for mouse IL-1β, CCL2 and TNF-α (Biolegend) following the manufacturer’s 502 
protocol. The VERSAmax microplate reader (Molecular Devices) was used for colorimetric 503 
quantification and analysis at 450nM wavelength.  504 
 505 
BCA protein assay. BCA protein assay kit was obtained from Thermo Scientific. 2µl of each BALF 506 
sample was used. VERSAmax microplate reader (Molecular Devices) was used for colorimetric 507 
quantification and analysis at 570nm wavelength. 508 
 509 
Plaque Assay. IAV plaque assays were performed as described before (55). Briefly, MDCK cells were 510 
grown in 6-well plates and incubated with series dilution of BALF for 1 h. The plates were then overlaid 511 
with low melting temperature agarose (0.6 %) in MEM with BSA and trypsin and cultured for 3 days in 512 
37°C incubator. Plates were then fixed with formaldehyde and virus plaques were visualized with the 513 
staining of neutral red. 514 
 515 
FACS analysis. Fluorescence-conjugated FACS Abs were purchased from Biolegend, BD Biosciences or 516 
eBioscience. Ab clones are provided. We defined cell populations based on following cell surface markers: 517 
AM (CD11c
+
 Siglec F
+
 CD11b
low
), Neutrophils (CD11b
+
 Ly6G
+
), total CD11b
+
 Monocyte/Macrophage 518 
population (Ly6G
-
 Siglec F
-
 CD11b
+
), Monocytes (Ly6G
-
 Siglec F
-
 CD11b
+
 Ly6C
+
), NP366 tetramer
+
 cells 519 
(CD8
+
 NP366-tet
+
), PA224 tetramer
+
 cells (CD8
+
 PA224-tet
+
). Samples were collected on FACS Attune or 520 
FACS Attune NXT flow cytometer (Life technologies) and analyzed using Flow Jo software (Tree Star). 521 
 522 
Statistical analysis. Data are mean ± SEM of values from individual mice (in vivo experiments). 523 
Unpaired two-tailed Student’s t-test (two group comparison), Multiple t-tests (weight loss) or Logrank 524 
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test (survival study) were used to determine statistical significance by GraphPad Prism software. We 525 
consider P values < 0.05 as significant.  526 
 527 
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FIGURE LEGENDS 704 
Figure 1. IAV down-regulates PPAR-γ expression in AM.  705 
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A. Comparison of the expression of 84 transcription factors in AM (isolated and pooled from at least 706 
3 mice) with or without IAV (IAV) infection for overnight in vitro by RT
2
 Profiler PCR array. 707 
Dotted line: fold cutoff of gene expression (1.5 fold). Red dots, genes up-regulated following IAV 708 
infection. Green dots, genes down-regulated following IAV infection. 709 
B. List of up- or down-regulated transcription factors in AM (isolated and pooled from at least 3 710 
mice) following IAV infection in vitro for overnight by RT
2
 Profiler PCR array. 711 
C. Relative expression of Pparg in AM (isolated and pooled from at least 3 mice) with or without 712 
IAV infection for overnight in vitro by qRT-PCR.  713 
D. Western blot analysis of PPAR-γ levels in AM (isolated and pooled from at least 3 mice) with or 714 
without IAV infection for overnight. Bar graph represents relative density of PPAR-γ band pooled 715 
from three independent experiments. 716 
E. Relative expression of Pparg in sorted AM isolated from non-infected (day 0) or IAV-infected 717 
mice at 4, 6, 10 or15 p.i 718 
F. Western blot analysis of PPAR-γ expression ex vivo in AM (isolated and pooled from at least 3 719 
mice) isolated from non-infected (day 0) or IAV-infected lungs (6 d.p.i.). Bar graphs represent 720 
relative density of PPAR-γ band pooled from three independent experiments. 721 
G. Western blot analysis of PPAR-γ expression in AM (isolated and pooled from at least 3 mice) with 722 
or without IFN-α treatment for overnight. Bar graph represent relative density of PPAR-γ band 723 
pooled from three independent experiments. 724 
H. Relative expression of Pparg in AM (isolated and pooled from at least 3 mice) with or without 725 
IAV infection in the presence or absence of α-IFNAR1 for overnight in vitro by qRT-PCR.  726 
I. STAT1 binding to Pparg loccus in AM following overnight IFN-α treatment in vitro was 727 
determined through ChIP (pooled from n>20 mice). Numbers in Red are distances of the binding 728 
sites to start codon. 729 
Data are representative of two to three independent experiments. *, P < 0.05. 730 
 731 
Figure 2. PPAR-γ suppresses antiviral inflammation, but not regulates M2 genes following infection 732 
A. Airway AM percentages and CD11b expression on AM from control (Ppargfl/fl) or PpargΔCD11c 733 
mice, and control or Pparg
ΔLyz2
 mice.  734 
B. Western blot of PPAR-γ expression in sorted AM (isolated and pooled from 2-3 mice) from 735 
control (Pparg
fl/fl
) or Pparg
 ΔLyz2
 mice at 0 and 3 d.p.i. 736 
 o
n
 April 24, 2020 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
C. qRT-PCR analysis of Ifna4, Ifnb1, Il1b, Tnf, Ccl2, Retnla and Arg1 expression in AM (isolated 737 
and pooled from 3 mice) from control (Pparg
fl/fl
) or Pparg
ΔLyz2
 mice following IAV infection in 738 
vitro for overnight. 739 
D. Control or PpargΔLyz2 mice were infected with IAV. Ifna4, Ifnb1, Tnf, Ccl2, Retnla and Arg1 gene 740 
expression in AM (isolated and pooled from 2-3 mice) of control or Pparg
ΔLyz2 
mice at day 1 and 3 741 
p.i. 742 
Data are representative of at least two independent experiments. *, P < 0.05.  743 
 744 
Figure 3. Myeloid PPAR-γ suppresses host mortality, morbidity and pulmonary inflammation.  745 
Control or Pparg
ΔLyz2
 mice were infected with IAV. 746 
A. Host mortality (% survival) was monitored.  747 
B. Host morbidity (% initial weight) was monitored. 748 
C. Airway IAV titers (pfu assay) were determined at day 4, 7, 10 or 15 p.i.. 749 
D. Lung IAV-specific PA224 and NP366 tetramer
+
 CD8
+
 T cells at day 7, 10 and 15 p.i. 750 
E. CCL2 and TNF-α levels in the BAL were quantified by ELISA at day 1, 3, 7, 10 or 15 p.i. 751 
F. Comparison of the expression of 84 inflammation-related genes in lungs from control or 752 
Pparg
ΔLyz2 
mice at day 10 p.i. by RT
2
 Profiler PCR array.  Dotted line: 1.5 fold difference cutoff. 753 
Red dots, genes up-regulated in the lungs of Pparg
ΔLyz2 
mice. Green dots, genes down-regulated in 754 
the lungs of Pparg
ΔLyz2 
mice.   755 
Data are representative of at least two independent experiments (n=3-6 mice per group) except A, B, 756 
C (pooled data from 2-6 experiments). *, P < 0.05.  757 
 758 
Figure 4. Myeloid PPAR-γ suppresses pulmonary inflammation during RSV infection.  759 
A. qRT-PCR analysis of Ifna4, Ifnb1, Il1b, Tnf, Ccl2, Retnla and Arg1 expression in AM (isolated 760 
and pooled from at least 3 mice) from control (Pparg
fl/fl
) or Pparg
ΔLyz2
 mice following RSV 761 
infection (10 MOI) in vitro for overnight. 762 
B-D. Control (Pparg
fl/fl
) or Pparg
ΔLyz2 
mice were infected with RSV.  763 
B. Host morbidity (% initial weight) was monitored daily.  764 
C. Numbers of lung neutrophils or monocytes at 4 d.p.i. 765 
D. BAL TNF and IL-1 concentrations were determined through ELISA at 4 d.p.i. 766 
Data are representative of at least two independent experiments (n=3-4 mice per group) except B 767 
(pooled data from 2 experiments). *, P < 0.05.  768 
 769 
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Figure 5. PPAR-γ expression in resident alveolar macrophages is likely required for the suppression 770 
of host morbidity  771 
A. Lyz2-cre gene recombination in AM, neutrophils and CD11b+ monocytes/macrophages is reported 772 
by % eYFP expression following crossing with R26R-eYFP reporter mice. 773 
B. Western blot analysis of PPAR-γ protein expression in sorted AM, CD11b+ 774 
monocytes/macrophages and neutrophils in the lungs from naïve WT mice (pooled from 3 mice). 775 
C. Tnf and Ccl2 expression in indicated cell populations in the lungs of control (Ppargfl/fl) or 776 
Pparg
ΔLyz2 
mice at day 1 and 3 p.i. (pooled from 2-3 mice per group). 777 
D. Ccr2-/- Ppargfl/fl and Ccr2-/- Pparg ΔLyz2 mice were infected with IAV. Host morbidity (% initial 778 
weight) was monitored. 779 
E. WT mice were infected with IAV and treated with control IgG or MC21 mAb. % lung AM (upper 780 
panel) and monocytes (lower panel) in CD45
+
 Ly6G
-
 cells are depicted at 5 d.p.i. 781 
F. Control (Ppargfl/fl) and PpargΔLyz2 mice were infected with IAV and treated with control IgG or 782 
MC21 mAb. Host morbidity (% initial weight) was monitored. 783 
Data are representative of at least two to three independent experiments except C (pooled data from 3 784 
experiments) and D. *, P < 0.05.  785 
 786 
Figure 6. Macrophage PPAR-γ modulates inflammation resolution and tissue repair.  787 
A. Comparison of the expression of 84 wound healing genes of AM isolated (pooled from 3 mice) 788 
from uninfected control or Pparg
ΔLyz2
 mice in vitro. Dotted line: fold cutoff of gene expression 789 
(1.5 fold). Red dots, genes up-regulated in PPAR-γ-deficient AM. Green dots, genes down-790 
regulated in PPAR-γ-deficient AM.   791 
B. List of up- or down-regulated wound healing genes in AM (pooled from 3 mice) from control or 792 
Pparg
ΔLyz2
 mice by RT
2
 Profiler PCR array. 793 
C-F. Control (Pparg
fl/fl
) or Pparg
ΔLyz2 
mice were infected with IAV (n=3-4).  794 
C. H&E staining of lung sections of control or PpargΔLyz2 mice at day 15 p.i.  Left panel, 795 
representative images. Right panel, quantification of percentages of inflamed and disrupted 796 
alveolar area in the lungs of control (Pparg
fl/fl
) and Pparg
ΔLyz2 
mice. 797 
D. BAL neutrophil or monocyte numbers were enumerated at 15 d.p.i. 798 
E. BAL total protein concentrations were determined at 1, 3, 7, 10 or 15 d.p.i. 799 
F. Sftpb and Abca3 gene expression in lungs from control or PpargΔLyz2 mice at 8, 10 or 15 d.p.i. 800 
Data are representative of at least two independent experiments, *, P < 0.05. 801 
 802 
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Figure 3 
0 5 10 15 20
0
20
40
60
80
100
Control (n=18)
PpargD Lyz2 (n=24)
d.p.i.
Pe
rc
en
t o
f s
u
rv
iv
al
P = 0.0021 
r Δ yz2 (n=24) 
tr l (  
7 10 15
0
2×105
4×105
6×105
8×105
d.p.i.
7 10 15
0
2×105
4×105
6×105
8×105
dpi
D 
Ce
ll #
 
Control 
PpargΔLyz2  
NP366+ PA224+ 
A B 
100 
90 
80 
70 
0 2 4 6 8 10 12 14 
%
 in
iti
al
 w
e
ig
ht
 
d.p.i. 
Control (n=6) 
110 
PpargΔLyz2 (n=17) 
Control (n=15) 
* 
* 
* 
* 
* * * 
* 
* 
* 
n.s. 
n.s. 
n.s. 
n.s. 
E 
Il6 
Cxcl9 
Fos 
Ccl2 
Ccr1 
Control 
Pp
ar
gΔ
Ly
z2
 
Inflammation-related genes 
pf
u/
m
l (L
o
g 1
0) 
Control 
PpargΔLyz2  C 
n.s. 
* 
n.s. 
d.p.i. 
4 7 10 15 
Co
n
c.
 
(pg
/m
l) 
* 
* 
Control 
PpargΔLyz2  
CCL2  
TNF 
* 
3 1 7 10 15 
d.p.i. 
F 
 o
n
 April 24, 2020 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
Figure 4 
A 
B C 
0.0
0.1
0.2
0.3
0.4
R
el
at
ive
 e
xp
re
ss
io
n
 
Ifna4 
Control 
PpargΔLyz2  
RSV - + + - 
0
5
10
15
Tnf 
- + + - 
0
5
10
15
0
1
2
3
0
2
4
6
- - + + - - + + - - + + 
Ifnb1 Il1b Ccl2 
0 1 2 3 4
80
90
100
d.p.i.
%
 
o
f i
n
itia
l w
e
igh
t
Control (n=7)
Pparg D Lyz2 (n=7)
* 
* 
* 
4 d.p.i. 
0
2×105
4×105
6×105
0.0
5.0×105
1.0×106
1.5×106
2.0×106
2.5×106
Control 
PpargΔLyz2  
Ce
ll #
 
Neutrophils Monocytes 
* * 
0
1
2
3
4
Arg1 
0
10
20
30
40
50
Retnla 
- - + + - - + + 
D 
0
100
200
300
400
0
50
100
150TNF 
pg
/m
l 
IL-1ȕ 
* 
* 
Control 
PpargΔLyz2  
 o
n
 April 24, 2020 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
Figure 5 
CD
11
b+
  
Mo
no
/M
Φ 
N
eu
tro
ph
ils
 
AM
  
PPAR-Ȗ 
Actin 
* 
110 
90 
80 
70 
0 2 4 6 8 10 12 14 
%
 in
iti
al
 w
e
ig
ht
 
d.p.i. 
Ccr2-/- PpargΔLyz2 (n=7) 
100 
60 
16 18 
Ccr2-/- Ppargfl/fl (n=12) 
* 
* 
* 
* 
Tnf 
Ccl2 
AM 
R
el
at
ive
 e
xp
re
ss
io
n
 
1        3   
d.p.i. 
0 
10 
50 
0 
0 
2 
4 
6 
8 
0 
1        3   
CD45- 
0 
0 
1        3   
20 
30 
40 
10 
20 
30 
40 
10 
10 
20 
30 
5 
10 
15 
20 
25 
20 
40 
60 
80 
CD11b+  
Mono/MΦ 
Control 
PpargΔLyz2  
0     2     4      6     8    10   12   14 
65 
85 
95 
105 
%
 in
iti
al
 w
e
ig
ht
 
75 
PpargΔLyz2 +IgG (n=5)  
Control + IgG (n=5) 
Control + MC21 (n=5) 
PpargΔLyz2 + MC21 (n=5) 
C 
D F 
B 
A 
<1 <1 <1 
83 74 24 
Rosa26-eYFP 
Lyz2-cre 
R26R-eYFP 
AM Neutrophils 
eYFP 
Si
gl
ec
 
F 
Ly
6G
 
CD
11
b 
CD11b+  
Mono/MΦ 
IgG MC21 
Si
gl
ec
 
F 8.5 10 
Gated on CD45+ Ly6G- cells  
CD11b 
Ly
6C
 
41 6 
5 d.p.i. 
CD11c 
E 
 o
n
 April 24, 2020 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
Figure 6 
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